N@N

Celgene Corp (NASDAQ:CELG), Down By 19.34% ($23.71) From $122.600 After BUYINS.NET Report Predicted Weakness Before Earnings

^{Published on 2013-04-18 05:45:25 - WOPRAI}
 

April 18, 2013 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, April 17th 2013 stating that Celgene Corp (NASDAQ:CELG) was expected to be Down Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=celg&id=361482

At the time this story was written, Celgene Corp (NASDAQ:CELG) is Down By 19.34% ($23.71) From $122.600 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

Celgene Corp (NASDAQ:CELG) - Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies to treat cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Its commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of patients with multiple myeloma and transfusion-dependent anemia; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk myelodysplastic syndromes (MDS), as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy treatment option for metastatic breast cancer; and THALOMID for patients with multiple myeloma, and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum. The company s commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound to treat chronic inflammatory conditions; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for the treatment of solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia in patients with blood disorders. The company s pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor, CC-292, a BTK inhibitor, CC-115, a dual TORK/DNA PK inhibitor, CC-122, a pleiotropic pathway modulator, and EPZ-5676, a DOT1L inhibitor. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey..

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Celgene Corp (NASDAQ:CELG) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net